טוען...
Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia
Aim: There is an unmet need in Japan for more optimal lipid-lowering therapy (LLT) for patients with homozygous familial hypercholesterolemia (HoFH) who respond inadequately to available drug therapies and/or apheresis, to achieve goals of low-density lipoprotein cholesterol (LDL-C) reduction by 50%...
שמור ב:
| הוצא לאור ב: | J Atheroscler Thromb |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Japan Atherosclerosis Society
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5392478/ https://ncbi.nlm.nih.gov/pubmed/28154305 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5551/jat.38216 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|